NO20060706L - Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease - Google Patents

Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease

Info

Publication number
NO20060706L
NO20060706L NO20060706A NO20060706A NO20060706L NO 20060706 L NO20060706 L NO 20060706L NO 20060706 A NO20060706 A NO 20060706A NO 20060706 A NO20060706 A NO 20060706A NO 20060706 L NO20060706 L NO 20060706L
Authority
NO
Norway
Prior art keywords
compounds
disclosed
inhibitors
serine proteases
ns4a protease
Prior art date
Application number
NO20060706A
Other languages
English (en)
Inventor
Janos Pitlik
Robert Perni
Shawn D Britt
Kevin M Cottrell
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34079432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060706(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO20060706L publication Critical patent/NO20060706L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Det beskrives forbindelser med formel I eUer formel la eUer farmasøytisk akseptable salter derav, som inhiberer serinproteaseaktivitet, spesielt aktiviteten av hepatitt C-virus-NS3-NS4A-protease. Som sådanne virker de ved å forstyrre livssyklusen for hepatitt C-virus og er nyttige som antivirale midler. Dessuten beskrives farmasøytisk akseptable sammensetninger omfattende forbindelsene enten for bruk ex vivo eller for administiasjon til en pasient som lider av HCV-infeksjon, og fremgangsmåter for frem- stUling av forbindelsene. Det beskrives også fremgangsmåter for å behandle en HCV-infeksjon i en pasient ved å administiere en farmasøytisk sammensetning som omfatter en forbindelse ifølge oppfmnelsen.
NO20060706A 2003-07-18 2006-02-14 Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease NO20060706L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48853503P 2003-07-18 2003-07-18
PCT/US2004/023054 WO2005007681A2 (en) 2003-07-18 2004-07-16 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease

Publications (1)

Publication Number Publication Date
NO20060706L true NO20060706L (no) 2006-02-14

Family

ID=34079432

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060706A NO20060706L (no) 2003-07-18 2006-02-14 Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease

Country Status (18)

Country Link
US (2) US7109172B2 (no)
EP (3) EP1646642A2 (no)
JP (2) JP4745230B2 (no)
KR (2) KR20060052836A (no)
CN (3) CN1852920B (no)
AR (1) AR045916A1 (no)
AU (2) AU2004257288A1 (no)
BR (1) BRPI0412761A (no)
CA (1) CA2532664A1 (no)
IL (2) IL173180A0 (no)
NO (1) NO20060706L (no)
NZ (1) NZ544789A (no)
PE (1) PE20050251A1 (no)
RU (1) RU2412198C2 (no)
TW (1) TW200523270A (no)
UY (1) UY28423A1 (no)
WO (1) WO2005007681A2 (no)
ZA (1) ZA200601420B (no)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1019A (en) * 1996-10-18 2001-10-16 Vertex Pharma Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
AU2001251165A1 (en) * 2000-04-03 2001-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
AU2003223602B8 (en) * 2002-04-11 2010-05-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis C virus NS3-NS4 protease
WO2004092161A1 (en) * 2003-04-11 2004-10-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP1646642A2 (en) * 2003-07-18 2006-04-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
UY28500A1 (es) * 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
WO2005028502A1 (en) * 2003-09-18 2005-03-31 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005037860A2 (en) * 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incoporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
CA2543696A1 (en) * 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Combinations for hcv treatment
WO2005077969A2 (en) * 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
BRPI0610283A2 (pt) 2005-05-13 2010-10-19 Virochem Pharma Inc composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica
NZ563361A (en) 2005-06-02 2011-02-25 Schering Corp HCV protease inhibitors in combination with food
NZ563365A (en) 2005-06-02 2011-02-25 Schering Corp Combination of HCV protease inhibitors with a surfactant
AU2006275413B2 (en) * 2005-08-02 2012-07-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
EP2392589A3 (en) 2005-11-11 2012-06-20 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
AU2007217355B2 (en) 2006-02-27 2012-06-21 Vertex Pharmaceuticals Incorporated Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
WO2007109080A2 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
AU2007249668B2 (en) * 2006-04-11 2011-04-07 Novartis Ag HCV/HIV inhibitors and their uses
PT2041156E (pt) 2006-07-13 2014-02-21 Achillion Pharmaceuticals Inc Péptidos 4-amino-4-oxobutanoil como inibidores da replicação viral
US20090035267A1 (en) * 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
US20080108632A1 (en) * 2006-11-02 2008-05-08 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
CA2670260A1 (en) 2006-11-15 2008-05-22 Virochem Pharma Inc. Thiophene analogues for the treatment or prevention of flavivirus infections
US20080161254A1 (en) * 2007-01-03 2008-07-03 Virobay, Inc. Hcv inhibitors
WO2008106058A2 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
HRP20120330T1 (hr) 2007-02-27 2012-05-31 Vertex Pharmaceuticals Incorporated Sukristali i farmaceutski pripravci koji ih sadrže
PT2144604E (pt) * 2007-02-28 2011-10-19 Conatus Pharmaceuticals Inc Métodos para o tratamento da hepatite c viral crónica utilizando ro-113-0830
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
US20090005387A1 (en) * 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
NZ583699A (en) 2007-08-30 2012-04-27 Vertex Pharma Co-crystals of vx-950 (telaprevir) other components and pharmaceutical compositions comprising the same
EP2364309B1 (en) 2008-12-10 2014-10-01 Achillion Pharmaceuticals, Inc. New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US20110182850A1 (en) * 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) * 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
PL2477980T3 (pl) 2009-09-15 2017-02-28 Taigen Biotechnology Co., Ltd. Inhibitory proteazy hcv
JP2013512247A (ja) 2009-11-25 2013-04-11 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染症の治療または予防のための５−アルキニル−チオフェン−２−カルボン酸誘導体およびそれらの使用
WO2011079327A1 (en) 2009-12-24 2011-06-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
CA2794145A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011119858A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
TW201141857A (en) 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
CN103038237A (zh) 2010-03-24 2013-04-10 沃泰克斯药物股份有限公司 用于黄病毒感染治疗或预防的类似物
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
WO2011159826A2 (en) 2010-06-15 2011-12-22 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
EP2585448A1 (en) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
AU2011276526A1 (en) 2010-06-28 2013-01-10 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
AU2011292040A1 (en) 2010-08-17 2013-03-07 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of Flaviviridae viral infections
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
WO2013016492A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Thiophene compounds
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
WO2013072328A1 (en) 2011-11-14 2013-05-23 Sanofi Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2014053533A1 (en) 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
US20150065439A1 (en) 2013-02-28 2015-03-05 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
CA2905433A1 (en) 2013-03-14 2014-09-25 Achillion Pharmaceuticals, Inc. Novel processes for producing sovaprevir
BR112015023351A2 (pt) 2013-03-15 2017-07-18 Achillion Pharmaceuticals Inc forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio
WO2014145507A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
SG11201703390SA (en) * 2014-10-27 2017-05-30 Inhibrx Lp Serpin fusion polypeptides and methods of use thereof
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
HUE064412T2 (hu) 2016-06-21 2024-03-28 Orion Ophthalmology LLC Heterociklusos prolinamid-származékok
JP7584418B2 (ja) 2018-12-04 2024-11-15 ブリストル－マイヤーズ スクイブ カンパニー 多重反応同位体分子種反応モニタリングによる、サンプル内検量線を用いた分析方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
AP1019A (en) 1996-10-18 2001-10-16 Vertex Pharma Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
DK0966465T3 (da) 1997-03-14 2003-10-20 Vertex Pharma Inhibitorer af IMPDH-enzymer
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
DK1066247T3 (da) 1998-03-31 2007-04-02 Vertex Pharma Inhibitorer af serinproteaser, især hepatitis C virus NS3 protease
CA2367017C (en) 1999-03-19 2009-05-26 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
AU2001251165A1 (en) * 2000-04-03 2001-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
CN1498224A (zh) * 2000-07-21 2004-05-19 ���鹫˾ 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
IL159087A0 (en) * 2001-07-11 2004-05-12 Vertex Pharma Bridged bicyclic compounds and pharmaceutical compositions containing the same
AU2002348414B2 (en) * 2001-10-24 2009-10-01 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
AU2003223602B8 (en) * 2002-04-11 2010-05-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis C virus NS3-NS4 protease
CA2495843A1 (en) 2002-09-04 2004-03-18 Mark Straubhaar Optoelectronic device for the treatment of muscle or joint pain
EP1636208B1 (en) * 2003-04-11 2012-02-29 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2004092161A1 (en) * 2003-04-11 2004-10-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP1646642A2 (en) 2003-07-18 2006-04-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
UY28500A1 (es) 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
WO2005028502A1 (en) 2003-09-18 2005-03-31 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005037860A2 (en) 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incoporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005077969A2 (en) 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
WO2008106058A2 (en) 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases

Also Published As

Publication number Publication date
KR20120013450A (ko) 2012-02-14
RU2006105002A (ru) 2006-08-27
EP2341065A2 (en) 2011-07-06
UY28423A1 (es) 2005-02-28
IL173180A0 (en) 2006-06-11
US7109172B2 (en) 2006-09-19
AU2010257200B2 (en) 2011-10-20
CN101724022A (zh) 2010-06-09
RU2412198C2 (ru) 2011-02-20
AU2010257200A1 (en) 2011-01-13
US20060211629A1 (en) 2006-09-21
WO2005007681A2 (en) 2005-01-27
IL218698A0 (en) 2012-05-31
EP2341065A3 (en) 2012-06-20
CA2532664A1 (en) 2005-01-27
AR045916A1 (es) 2005-11-16
KR20060052836A (ko) 2006-05-19
WO2005007681A3 (en) 2005-06-02
TW200523270A (en) 2005-07-16
EP2368900A3 (en) 2012-07-04
EP2368900A2 (en) 2011-09-28
US8691758B2 (en) 2014-04-08
ZA200601420B (en) 2007-06-27
JP4745230B2 (ja) 2011-08-10
CN1852920A (zh) 2006-10-25
HK1098164A1 (en) 2007-07-13
BRPI0412761A (pt) 2006-09-26
CN1852920B (zh) 2010-12-15
AU2004257288A2 (en) 2008-06-26
US20050107304A1 (en) 2005-05-19
JP2008500265A (ja) 2008-01-10
PE20050251A1 (es) 2005-04-13
AU2004257288A1 (en) 2005-01-27
JP2011116784A (ja) 2011-06-16
NZ544789A (en) 2010-01-29
EP1646642A2 (en) 2006-04-19
CN102020700A (zh) 2011-04-20

Similar Documents

Publication Publication Date Title
NO20060706L (no) Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease
NO20062101L (no) Serinproteaseinhibitorer, spesielt hcv ns3-ns4a-protease
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
WO2005077969A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2004093798A3 (en) Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
WO2005035525A3 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
ATE349463T1 (de) Verbrückte bizyklische serinproteaseinhibitoren
WO2004113365A3 (en) Hepatitis c serine protease tri-peptide inhibitors
EP1441720B8 (en) Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
NO20072286L (no) Hemming av HCV NS3-NS4A-protease
WO2004072243A3 (en) Macrocyclic hepatitis c serine protease inhibitors
WO2008002924A3 (en) Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2003087092A3 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
WO2008021960A3 (en) Triazolyl macrocyclic hepatitis c serine protease inhibitors
WO2009053828A3 (en) P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
WO2008021871A3 (en) Triazolyl acyclic hepatitis c serine protease inhibitors
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
WO2007143694A3 (en) Macrocyclic oximyl hepatitis c protease inhibitors
WO2008106058A3 (en) Inhibitors of serine proteases
WO2008022006A3 (en) Arylalkoxyl hepatitis c virus protease inhibitors
WO2009076173A3 (en) Fluorinated tripeptide hcv serine protease inhibitors
MX2010006209A (es) Derivados de quinoxalinilo.
WO2008019303A3 (en) Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors
WO2008019266A3 (en) Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application